Pay in 4 interest-free payments of $5.67 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Todaro, B., Ottalagana, E., Luin, S., & Santi, M
Higher-dose formulations of semaglutide (Wegovy, 2.4 mg weekly) and tirzepatide (Zepbound, up to 15 mg weekly) are approved specifically for chronic weight management in non-diabetic patients
A qualitative analysis of 660 posts on r/WegovyWeightLoss from October 2022 through October 2023 (PMC12327412) found many users describing near-total food noise reduction and the end of binge urges, while a distinct subset reported cravings sharpened into binges when stress remained unmanaged
Many clients notice a reduction in hunger and cravings, helping them eat smaller portions and feel fuller faster
People who abandon treatment in month two frequently do so believing the medication didn't work for them, when it hadn't yet reached the dose at which it was studied
